Assessment of Health Risks of Red Sludge Exposition by Tibold Antal
1 
 
 
 
Assessment of health risks of red sludge exposition 
Ph.D. thesis  
Author: Antal Tibold, MD 
 
Clinical Medical Sciences Doctoral School 
Head of Doctoral School: 
Gábor L. Kovács MD, PhD, DSc 
 
Program Director: 
István Kiss MD, PhD, DSc 
István Ember MD, PhD, DSc 
 
 
University of Pécs  
2016 
2 
 
 
INTRODUCTION 
 
Red mud or red sludge is a waste product of the Bayer process, the principal 
industrial means of refining bauxite in order to provide alumina as raw material for 
the production of aluminium. The red color originates from iron (III)oxide, the main 
component, which can make up to 60% of the mass of the red mud. In addition to 
iron, the other dominant particles include silica, unleached residual aluminium, and 
titanium oxide. The mud is highly alkaline with a pH ranging from 10 to 13. Red 
mud represent one of the biggest disposal problems of industry, usually it is stored 
in large open-air ponds. 
In October 2010, approximately 1.5 million m
3
 of red mud flooded Kolontár and 
other nearby locations in Hungary in the Ajka alumina plant accident, killing ten 
people and contaminating about 40 km
2
 of land. The accident had deleterious 
ecological, physiological and financial effects.  After the accident several studies 
examined the geochemical and toxicological properties of red mud. The team 
leading containment and the clean-up process tried to estimate the risk of health 
damage caused by the exposure. Heavy metal contamination of the soil exceeded 
the “B” contamination limit. Cytogenetical measurements performed in 17 victims 
who suffered chemical burns as well as in 35 people taking part in the clean-up. 
Compared to non-exposed controls, no significant difference was found, so 
genotoxic effect of red mud exposure was not proved in the examined individuals.  
Other examinations studied the mutagenic and cytotoxic effects of red mud. Based 
on the results of MTT and Ames tests no genotoxical and citotoxical effects were 
found.  
However, red mud-induced alterations on gene expression and microRNA have not 
yet been examined. Environmental factors induce cascades of epigenetic and 
genomic regulatory mechanisms essential for survival and adaptation, while early-
immediate responses mostly involve alterations in gene expression, and changes in 
the expression of microRNA playing a key role in the process of cell cycle, 
apoptosis and differentiation. This indicates that certain miRNA being in charge for 
the regulation of mRNA are suitable to predict and follow-up various environmental 
effects.  In my work I aimed to examine the early changes in the expression of 
onco- and suppressor genes (c-myc, K-ras, p53, Bcl2) and microRNAs (miR-21, 
miR-27a, miR-93, miR-221) caused by the intraperitoneal administration of red 
mud. 
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AIMS 
 
1. Examination of expression patterns of onco/suppressor genes: 
I aimed to investigate whether changes of onco/suppressor gene expression 
were detectable following  experimental red sludge exposition. 
2. Examination of targeted microRNA expression profile: 
I aimed to investigate whether there are changes of microRNA expression 
due to experimental red sludge exposition 
3. I aimed to clear in view of the expression of onco/suppresor genes and 
micrRNA: 
- what health risk consequences can be drawn concerning red sludge 
exposition 
- how results relate to the outcome of other examinations in 
connection with the red sludge disaster   
4. I aimed to clear what conclusions could be drawn concerning the adaptation 
of onco/suppresor genes and microRNA as early biomarkers based on the 
results. 
  
 
MATERIALS AND METHODS 
 
Sample 
Red mud was collected exactly from the place, and on the day of the disaster, in the 
valley of Torna. The red mud was stored at a dark, temperated place, in hermetically 
closed containers. Before using it, we dried the mud over 24 h on 60°C, then the 
samples were diluted with distilled water to the required concentration.  
 
Experimental testing system 
Five groups of CBA/Ca (H-2K haplotype) male mice were used for the experiment. 
The animals were six weeks old (20±4 g) and were kept in isolated cages. The 
control group consumed the standard laboratory pellet and tap water ad libitum. 
Four groups of mice received a single intraperitoneal gavage of dried red mud, 25 
mg/body weight dose, (0.5 mg/0.1 ml solved in distilled water). The control group 
was treated with distilled water. One, three, six and twenty-four hours after red mud 
injection mice were autopsied after cervical dislocation. The liver, lung, kidneys, 
spleen and lymph nodes of the animals were removed and 100-mg samples were 
obtained from each tissue of the respective groups. 
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Total RNS isolation 
 After homogenization of the organs, total cellular RNA was isolated using 
TRIZOL reagent (Invitrogen, Paisley, UK). The RNA quality was checked by 
denaturing gel-electrophoresis, and absorption measurement was performed at 
260/280 nm (A260/A280 was over 1.8). 
 
Examination of messenger RNA expression 
 Ten μg RNA were dot-blotted onto Hybond N+ nitrocellulose membrane (ECL kit, 
Amersham, Little Chalfont, UK) and hybridized with chemiluminescently labelled 
specific probes for cmyc, p53, bcl2 and Kras genes. Isolation of RNA, hybridization 
and detection were performed according to the manufacturer’s instructions. The 
membranes were rehybridized with constitutively expressed beta-actin gene as a 
positive control. The chemiluminescent signals were detected on X-ray films, 
scanned into a computer and evaluated by Quantiscan 2.0 software (Biosoft, 
Cambridge, UK). Gene expression is reported as percentage relative to the level of 
the expression of β-actin control.   
 
Examination of microRNA ecpression 
The expression of the investigated miRNAs was determined by quantitative real-
time polymerase chain reaction (PCR). Total RNA was exposed to RNAase-free 
DNAase and 2 μl was reverse transcribed into cDNA using Transcriptor First 
Strand cDNA Synthesis Kit (Roche, Berlin, Germany). PCR primers were designed 
using the primer finder database (www.applied-science.roche.com) and were 
synthesized by TIB Molbiol, ADR Logistics, (Roche Warehouse, Budapest, 
Hungary). Sequence specific primers:  
miR-21 forward: 5’- GCTTATCAGACTGATGTTGACTG -3’,  
reverse: 5’- CAGCCCATCGACTGGTG-3’;  
miR-27a forward: 5’- GCAGGGCT TAGCTGCTTG-3’,  
reverse: 5’- GGCGGAACTTAGCCACTGT-3’;  
miR-93 forward: 5’-AAGTGCTGTTCGTGCAGGT-3’,  
reverse: 5’- CTCGGGAAGTGCTAGCTCA-3’,  
miR-221 forward: 5’-CCTG GCATACAATGTAGATTTCTG-3’,  
reverse: 5’-AAACCCAGCAG ACAATGTAGCT-3’.  
 
The PCR was performed on a LightCycler 480 PCR system (Roche, Berlin, 
Germany). The PCR reaction mixture contained: 5 μl of template cDNS, 3 μl of 
H2O, 2 μl specific primer and 10 μl Master mix. The reaction mixtures were 
incubated in LightCycler 480 Multiwell Plate 96, for 5 min at 95˚C, followed by 55 
three-step amplification cycles (95˚C for 10 s, 55˚C for 20 s, 72˚C for 15 s).  
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miRNA expressions were determined by absolute nucleic acid quantification with 
480 Light Cycler software (Roche Diagnostics GmbH, Mannheim, Germany).  
 
Statistical analysis 
The statistical calculation of differences in expression was performed using 
Statistical Program for Social Science 19.0 (SPSS) software (IBM, Armonk, NY, 
USA). Student’s t-test was performed between control and treated groups, and p-
values less than 0.05 were considered statistically significant. 
 
RESULTS 
Using quantitative real-time polymerase chain reaction the expression profile of 
apoptosis-regulatory onco- and tumor suppressor genes and miRNAs in vital organs 
of CBA/Ca mice were evaluated at 1-, 3-, 6- and 24-h time point following 
intraperitoneal injection of red sludge. Statistical significanses indicated with star 
signs. 
     
Figure 1. Onco- and tumor suppressor gene expressions in the liver
       
Figure 2. Onco- and tumor suppressor gene expressions in the spleen
                                   
 
     
Figure 3. Onco- and tumor suppressor gene expressions in the lung     Figure 4. ábra: Onco- and tumor /suppressor gene expressions in the kidneys 
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Figure 5. Onco- and tumor suppressor géne expressions in lymph nodes   Figure 6. miRNA expressions in the liver 
 
 
 
         
 Figure 7. miRNA expressions in the spleen                                                 Figure 8. miRNA expressions in the lung 
 
         
Figure 9. miRNA expressions in the kidneys                                                Figure 10. miRNA expressions in lymph nodes  
 
One hour after the treatment we detected a significant upregulation of c-Myc in the 
liver and spleen (Figures 1,2), while there was a significant down-regulation in the 
expression of p53 in the lung, kidneys and lymph nodes (Figures 3-5).  
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Considerably increased expression of K-ras gene was found in the liver, lungs and 
kidneys. 3 h after the injection of red sludge (Figures 1, 3 and 4). The expression of 
Bcl2 gene showed upregulation in the spleen, lungs and kidneys at the 3-h time 
point (Figures 2-4). The expession of c-myc was decreased in the liver and lymph 
nodes at the specific time point (Figures 1 and 5). In the lungs, the expression levels 
of all investigated mRNAs were significantly elevated 6 h after the exposure with 
red sludge, while the lymph nodes showed decreased expression of the same 
mRNAs at the same time (Figures 3 and 5). We observed a significant up-regulation 
of the investigated mRNAs in the liver and spleen and their down-regulation in the 
lymph nodes 24 h after the treatment with red sludge (Figures 1, 2 and 5).  
In the liver, miR-93 showed a significantly increased expression level relative to the 
control group at the 1-h time point (Figure 6), and miR-21 at 1-h, 3-h, 6-h, 24-h 
points. In the kidneys, we observed a marked decrease in the expression of miR-27a 
and miR-221 at the 1- and 24-h time point (Figure 9). A significant up-regulation of 
miR-93 was detected 3 hours and 24 h after the exposure in the lymph nodes 
(Figure 10). 
 
 
DISCUSSION 
 
The results of my studies prove the existence of early gene expression changes in 
mice after intraperitoneal administration of red mud. Intraperitoneal administration 
of red mud was proved to change the expression of several mRNAs and miRNAs 
that play a role in the processes of cell proliferation, differentiation, signal 
transduction and apoptosis.  
 The results raise the possibility of long-term deleterious health effects of red mud 
in humans. As our investigation was limited to the first 24 h after the administration 
of red sludge, it is not known wether the observed effect is permanent or temporary, 
thus the gene expression changes caused by red sludge require longer-term 
investigations with more genes. Chosing the appropriate target genes and adequate 
miRNA, mRNAand miRNA expressions may be promising biomarkers of 
carcinogen exposition.  Their advantege is that they are not specific to a certain 
agent, and they can signal the carcinogenic effect of genotoxic and non-genotoxic 
exposures.   
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SUMMARY 
1)  short term animal tests confirmed that exposure to red mud causes significant 
changes in the expression of oncogenes and supressor genes. 
2) short term animal tests confirmed that the exposure to red mud causes significant 
changes in the expression microRNA-s. 
3)   the changes of expressions manifestated within 24 hours. 
4)  results  do not confirm  supposed neutral health effects of  red mud. 
5)  usefulness of traditional cytogenetical methods  is limited for assessing possible 
health risks caused by red mud exposure. 
6)     The changes of expression of onco and supressor genes and microRNA-s are 
potentially useful  biomarkers, which: 
-         can detect exposure to non genotoxical agents, 
-         can detect exposure within a short period, 
-         can follow up the acute changes caused by the exposure, 
-         can be isolated from the easily collectible samples, 
-         can be used for monitoRing the effects of mixed exposures. 
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